Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma

• Verfasst von: Wehling, Cyrill [VerfasserIn]
• Verfasst von: Hornuß, Daniel [VerfasserIn]
• Verfasst von: Springfeld, Christoph [VerfasserIn]
• Verfasst von: Hoffmann, Katrin [VerfasserIn]
• Verfasst von: Chang, De-Hua [VerfasserIn]
• Verfasst von: Naumann, Patrick [VerfasserIn]
• Verfasst von: Mieth, Markus [VerfasserIn]
• Verfasst von: Longerich, Thomas [VerfasserIn]
• Verfasst von: Kratochwil, Clemens [VerfasserIn]
• Verfasst von: Mehrabi, Arianeb [VerfasserIn]
• Verfasst von: Gauss, Annika [VerfasserIn]
• Verfasst von: Weiss, Karl Heinz [VerfasserIn]
• Verfasst von: Pfeiffenberger, Jan [VerfasserIn]
• Titel: Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma
• Verf.angabe: Cyrill Wehling, Daniel Hornuss, Pasquale Schneider, Christoph Springfeld, Katrin Hoffmann, De-Hua Chang, Patrick Naumann, Markus Mieth, Thomas Longerich, Clemens Kratochwil, Arianeb Mehrabi, Annika Gauss, Karl Heinz Weiss, Jan Pfeiffenberger
• E-Jahr: 2019
• Jahr: 19 August 2019
• Umfang: 9 S.
• Fussnoten: Gesehen am 14.11.2019
• Titel Quelle: Enthalten in: Journal of cancer research and clinical oncology
• Ort Quelle: Berlin : Springer, 1904
• Jahr Quelle: 2019
• Band/Heft Quelle: 145(2019), 11, Seite 2761-2769
• ISSN Quelle: 1432-1335
• DOI: doi:10.1007/s00432-019-03005-y
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Hepatocellular carcinoma
• Sach-SW: Quality of life
• Sach-SW: SF36
• Sach-SW: Sorafenib
• Sach-SW: TACE
• K10plus-PPN: 1681878763

Abstract

Purpose: This study aims to examine the health-related quality of life in patients with hepatocellular carcinoma. Methods: 181 patients attending a tertiary center outpatient clinic were interviewed and completed the short form 36 (SF36) questionnaire. The SF36 was used to assess health-related QoL. Cross-sectional analyses by group (age, gender, clinical scores, systemic, and local interventions) as well sequel questionnaires were conducted. Results: Participants included were 79% (143/181) men [mean age at first SF36: 63.8 (± 12.3; 18.4-85.8) years]. Barcelona Clinic Liver Cancer (BCLC) stadium C was associated with significantly lower SF36 total scores, and elevated initial alpha-fetoprotein (AFP) concentrations were associated with lower SF36 functional and mental health sum scores throughout the course of the third questionnaire. Patients treated with sorafenib had within the sub-dimension scores a significantly lower result for role limitations due to physical health compared to patients without sorafenib treatment. Patients who underwent a transarterial chemoembolization (TACE) had within the sub-dimension scores a significantly higher result for control of pain compared to patients without TACE. Kaplan-Meier analysis revealed significant survival benefits for patients who underwent any intervention at the first SF36 (mean survival in years 4.3 vs. 1.6; P < 0.01) as well as for patients who underwent hepatic resection (mean survival in years 6.3 vs. 2.7; P < 0.0001). Conclusion: Advanced tumor stages marked by BCLC stadium C and elevated initial AFP concentrations were associated with lower SF36 total scores and functional sum scores, respectively. During the course of sorafenib treatment, the sub-dimensional score for role limitations due to physical health decreased significantly, whereas TACE performance was associated with a significant improvement of the control of body pain.